Spironolactone for Single Ventricle Heart Condition
Trial Summary
What is the purpose of this trial?
The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.
Will I have to stop taking my current medications?
If you are currently taking spironolactone, eplerenone, or certain blood pressure medications like enalapril, you may need to stop these before joining the trial. The protocol does not specify other medications, so it's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug Spironolactone for treating heart conditions?
Is spironolactone generally safe for use in humans?
How is the drug spironolactone unique for treating single ventricle heart condition?
Spironolactone is unique because it not only acts as a diuretic but also has direct effects on the heart, such as reducing cardiac fibrosis (scarring of heart tissue) and improving heart function, which may benefit patients with single ventricle heart conditions by potentially aiding in cardiac tissue regeneration and remodeling.145910
Eligibility Criteria
This trial is for children aged 1 to less than 6 with a single ventricle heart defect, scheduled for Fontan surgery at CHOP. It includes those who agree to MRI scans under sedation and whose parents consent. Excluded are kids already on spironolactone or similar drugs, with severe kidney issues, hyperkalemia, Addison disease, or conditions making the trial harmful.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-Fontan Assessment
Characterization and measurement of liver and cardiac fibrosis with MRI and CMR as well as serum biomarkers immediately prior to the Fontan operation
Post-Fontan Treatment
Administration of spironolactone and follow-up assessments including MRI and CMR to evaluate fibrosis and lymphatic function
Follow-up
Participants are monitored for safety and effectiveness after treatment, including evaluation of liver and cardiac fibrosis and lymphatic function
Treatment Details
Interventions
- Spironolactone (Mineralocorticoid Receptor Antagonist)
Spironolactone is already approved in United States, European Union for the following indications:
- High blood pressure
- Heart failure
- Liver scarring
- Kidney disease
- Low blood potassium
- Early puberty in boys
- Acne
- Excessive hair growth in women
- Fluid retention due to heart failure
- Liver scarring
- Kidney disease
- High blood pressure
- Low blood potassium